Compare Cytokinetics Inc (CYTK) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs NextEra Energy, Inc. — how do they compare? Cytokinetics Inc trades at $82.38 (market cap $11.12B), while NextEra Energy, Inc. trades at $88.93 (market cap $186.75B). The key difference: NextEra Energy, Inc. is far larger — about 16.8× Cytokinetics Inc's market cap, and NextEra Energy, Inc. pays a 2.78% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | NEE | |
|---|---|---|
Market Cap | $11.12B | $186.75B |
Sector | Technology | Utilities |
52-Week High | $87.26 | $97.88 |
52-Week Low | $33.23 | $69.77 |
Enterprise Value | $11.59B | $289.15B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
NextEra Energy (NEE) trades at $88.38, up 0.48% with neutral technical signals. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though revenue growth has been volatile. Recent earnings beat expectations in Q1 2026, with Q2 results due July 24. Analyst consensus is strongly bullish with $103 price target, while technical indicators show RSI at neutral levels with support at $87-88.
NEE presents a compelling utility investment with clean energy leadership and dividend growth potential, though faces risks from capital expenditure demands and regulatory uncertainty. The stock trades below analyst targets with institutional support, but investors should monitor execution on the Dominion deal and AI-driven power demand trends that could impact future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
